{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:39:48Z","timestamp":1780375188374,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.amjopharm.2010.08.004","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T04:43:58Z","timestamp":1285389838000},"page":"316-330","source":"Crossref","is-referenced-by-count":37,"title":["Management of hallucinations and psychosis in Parkinson's disease"],"prefix":"10.1016","volume":"8","author":[{"given":"Marty L.","family":"Eng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Welty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2010.08.004_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","article-title":"Prospective study of hallucinations and delusions in Parkinson's disease","volume":"70","author":"Holroyd","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Arch Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2007.08.010","article-title":"Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease","volume":"109","author":"Meral","year":"2007","journal-title":"Clin Neurol Neurosurg."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2377-8-21","article-title":"A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease","volume":"8","author":"Papapetropoulos","year":"2008","journal-title":"BMC Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib5","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22195","article-title":"Estimate of point prevalence of Parkinson's disease induced psychosis in the United States","volume":"23","author":"Holt","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.parkreldis.2006.03.006","article-title":"Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease","volume":"12","author":"Weintraub","year":"2006","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00415-005-0918-5","article-title":"Psychotic symptoms in Parkinson's disease. From description to etiology","volume":"252","author":"Papapetropoulos","year":"2005","journal-title":"J Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00415-005-0840-x","article-title":"Factors associated with drug-induced visual hallucinations in Parkinson's disease","volume":"252","author":"Papapetropoulos","year":"2005","journal-title":"J Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","article-title":"Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease","volume":"107","author":"Giladi","year":"2000","journal-title":"J Neural Transm."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2377-9-23","article-title":"Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: A case-control study","volume":"9","author":"Ecker","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2008.09.003","article-title":"The association between motor subtypes and psychopathology in Parkinson's disease","volume":"15","author":"Reijnders","year":"2009","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/WNN.0b013e318185e698","article-title":"Hallucinations, dreaming, and frequent dozing in Parkinson disease: Impact of right-hemisphere neural networks","volume":"21","author":"Stavitsky","year":"2008","journal-title":"Cogn Behav Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","article-title":"Risk factors for somnolence, edema, and hallucinations in early Parkinson disease","volume":"69","author":"Biglan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","article-title":"Prospective longitudinal assessment of hallucinations in Parkinson's disease","volume":"57","author":"Goetz","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mds.20263","article-title":"Hallucinations in Parkinson's disease: A follow-up study","volume":"20","author":"de Maindreville","year":"2005","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib17","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson's disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","article-title":"Mortality and hallucinations in nursing home patients with advanced Parkinson's disease","volume":"45","author":"Goetz","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib19","first-page":"642","article-title":"Mortality and hallucinations in Parkinson's disease: A four-year longitudinal study","volume":"9","author":"Aarsland","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib23","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/s100720200084","article-title":"Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease","volume":"23","author":"Morgante","year":"2002","journal-title":"Neurol Sci."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4088\/JCP.v62n0810","article-title":"A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments","volume":"62","author":"Ballard","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JGP.0b013e318167ae76","article-title":"The course of psychiatric and behavioral symptoms and the use of psychotropic medications in patients with dementia in Norwegian nursing homes-a 12-month follow-up","volume":"16","author":"Selbaek","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","article-title":"The validity of the Clinicians Global Impression severity and improvement scales as measures for clinical effectiveness suitable for routine clinical use","volume":"14","author":"Berk","year":"2008","journal-title":"J Eval Clin Pract."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: Onset, progression, mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archpsyc.1983.01790060110016","article-title":"The mini-mental state examination","volume":"40","author":"Folstein","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib32","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib33","first-page":"280","article-title":"Parkinson's Psychosis Rating Scale: A practical instrument for grading psychosis in Parkinson's disease","volume":"2","author":"Freidberg","year":"1998","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the Positive and Negative Symptoms Scale mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizo Res."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib35","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorders Society-Sponsored revision of Unified Parkinson's Disease Rating Scale: Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","article-title":"Long-term outcome of clozapine use for psychosis in parkinsonian patients","volume":"19","author":"Fernandez","year":"2004","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1590\/S0004-282X2008000500001","article-title":"Use of clozapine in Brazilian patients with Parkinson's disease","volume":"66","author":"Gomide","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002826-200401000-00010","article-title":"Longterm evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease","volume":"27","author":"Mancini","year":"2004","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.10620","article-title":"Quetiapine improves psychotic symptoms and cognition in Parkinson's disease","volume":"19","author":"Juncos","year":"2004","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00415-005-0943-4","article-title":"The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview","volume":"253","author":"Prohorov","year":"2006","journal-title":"J Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.WNF.0000228176.98582.93","article-title":"Long-term follow-up (24 months) of quetiapine treatment in druginduced Parkinson disease psychosis","volume":"29","author":"Klein","year":"2006","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib45","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.004_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.amjopharm.2010.08.004_bib48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","article-title":"Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594610000681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594610000681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T16:27:34Z","timestamp":1544200054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594610000681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1543594610000681"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2010.08.004","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}